Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Construction In Progress : ¥221 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Construction In Progress?

Hunan Er-Kang Pharmaceutical Co's quarterly construction in progress increased from Sep. 2023 (¥214 Mil) to Dec. 2023 (¥221 Mil) and increased from Dec. 2023 (¥221 Mil) to Mar. 2024 (¥221 Mil).

Hunan Er-Kang Pharmaceutical Co's annual construction in progress declined from Dec. 2021 (¥506 Mil) to Dec. 2022 (¥53 Mil) but then increased from Dec. 2022 (¥53 Mil) to Dec. 2023 (¥221 Mil).

Hunan Er-Kang Pharmaceutical Co Construction In Progress Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Construction In Progress Chart

Hunan Er-Kang Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

285.88

408.21

506.18

52.92

220.89

Hunan Er-Kang Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial															68.55	171.69	214.15	220.89	221.26

Hunan Er-Kang Pharmaceutical Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Construction In Progress

Traded in Other Exchanges

N/A

Address

Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331

Website

http://www.hnerkang.com

Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines